Isolation in Brazil of Nosocomial Staphylococcus aureus With Reduced Susceptibility to Vancomycin

Abstract Objective: To evaluate the possible presence of vancomycin-resistant Staphylococcus aureus (VRSA) in a Brazilian hospital. Design: Epidemiological and laboratory investigation of nosocomial VRSA Methods: 140 methicillin-resistant S aureus strains isolated between November 1998 and October 1999 were screened for susceptibility to vancomycin. The screening was carried out by using brain-heart infusion agar (BHIA) supplemented with 4, 6, and 8 μg/mL of vancomycin. The minimum inhibitory concentration (MIC) determination was carried out as standardized by the National Committee for Clinical Laboratory Standards using the broth macrodilution, agar-plate dilution, and E-test methods. Patients: Hospitalized patients exposed to vancomycin. Results: 5 of the 140 isolates had a vancomycin MIC of 8 μg/mL by broth macrodilution, agar plate dilution, and E-test methods. Four VRSA strains were isolated from patients in a burn unit who had been treated with vancomycin for more than 30 days, and one from an orthopedic unit patient who had received vancomycin treatment for 7 days. Pulsed-field gel electrophoresis characterized four of the VRSA strains as belonging to the Brazilian endemic clone. All five strains were negative for vanA, vanB, and vanC genes by polymerase chain reaction. Transmission electron microscopy of the five strains revealed significantly thickened cell walls. One patient died due to infection caused by the VRSA strain. Conclusions: This is the first report of isolation of VRSA in Brazil and the first report of isolation of multiple VRSA strains from one facility over a relatively short period of time. This alerts us to the possibility that VRSA may be capable of nosocomial transfer if adequate hospital infection control measures are not taken.

[1]  Arjun Srinivasan,et al.  Vancomycin Resistance in Staphylococci , 2002, Clinical Microbiology Reviews.

[2]  K. Hiramatsu,et al.  Vancomycin-resistant Staphylococcus aureus occurs in South Africa. , 2000, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[3]  C. Pai,et al.  Vancomycin-Intermediate Staphylococcus aureus in Korea , 2000, Journal of Clinical Microbiology.

[4]  H. Murakami,et al.  Contribution of a Thickened Cell Wall and Its Glutamine Nonamidated Component to the Vancomycin Resistance Expressed by Staphylococcus aureus Mu50 , 2000, Antimicrobial Agents and Chemotherapy.

[5]  R. Jayaswal,et al.  Characterization of Passage-Selected Vancomycin-Resistant Staphylococcus aureus Strains of Diverse Parental Backgrounds , 2000, Antimicrobial Agents and Chemotherapy.

[6]  S. Boyle-Vavra,et al.  Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates , 2000, Antimicrobial Agents and Chemotherapy.

[7]  F. Tenover Implications of vancomycin-resistant Staphylococcus aureus. , 1999, The Journal of hospital infection.

[8]  R. Gaynes,et al.  Glycopeptide-Intermediate Staphylococcus aureus: Evaluation of a Novel Screening Method and Results of a Survey of Selected U.S. Hospitals , 1999, Journal of Clinical Microbiology.

[9]  A. MacGowan,et al.  Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. , 1999, The Journal of antimicrobial chemotherapy.

[10]  J. Aeschlimann,et al.  Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.

[11]  G. Archer,et al.  Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin , 1999, Antimicrobial Agents and Chemotherapy.

[12]  A. Tomasz,et al.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.

[13]  B. Robinson-Dunn,et al.  Emergence of Vancomycin Resistance inStaphylococcus aureus , 1999 .

[14]  K. Hiramatsu,et al.  Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. , 1998, The Journal of antimicrobial chemotherapy.

[15]  R. Dal-Ré,et al.  In Vitro Activities of Co-Amoxiclav at Concentrations Achieved in Human Serum against the Resistant Subpopulation of Heteroresistant Staphylococcus aureus: a Controlled Study with Vancomycin , 1998, Antimicrobial Agents and Chemotherapy.

[16]  K. Hiramatsu The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. , 1998, The American journal of medicine.

[17]  C. Martín,et al.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital , 1998, The Lancet.

[18]  F. Tenover,et al.  Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides , 1998, Journal of Clinical Microbiology.

[19]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[20]  Centersfordiseasecontrolandpr Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. , 1997, MMWR. Morbidity and mortality weekly report.

[21]  F. Tenover,et al.  Detection of vancomycin-resistant enterococci in fecal samples by PCR , 1997, Journal of clinical microbiology.

[22]  L. Doğancı,et al.  Overdiagnosis of intestinal amoebosis in Turkey , 1997, The Lancet.

[23]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[24]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[25]  A. Tomasz,et al.  Geographic spread of epidemic multiresistant Staphylococcus aureus clone in Brazil , 1995, Journal of clinical microbiology.

[26]  R. S. Grinbaum,et al.  An Overview of Nosocomial Infection Control in Brazil , 1995, Infection Control & Hospital Epidemiology.

[27]  Ronald N. Jones,et al.  Evaluation of Interhospital Spread of Methicillin-Resistant Staphylococcus aureus in Sao Paulo, Brazil, Using Pulsed-Field Gel Electrophoresis of Chromosomal DNA , 1994, Infection Control & Hospital Epidemiology.

[28]  F. Tenover,et al.  Characterization of glycopeptide-resistant enterococci from U.S. hospitals , 1993, Antimicrobial Agents and Chemotherapy.

[29]  R. Goering,et al.  Molecular Epidemiology of Nosocomial Infection: Analysis of Chromosomal Restriction Fragment Patterns by Pulsed-Field Gel Electrophoresis , 1993, Infection Control & Hospital Epidemiology.

[30]  T. Rice Simplified dosing and monitoring of vancomycin for the burn care clinician. , 1992, Burns : journal of the International Society for Burn Injuries.

[31]  F. Tenover,et al.  Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. , 1999, Emerging infectious diseases.